A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study

AIMS: To compare the efficacy and safety of adding low‐dose lobeglitazone (0.25 mg/day) or standard‐dose lobeglitazone (0.5 mg/day) to patients with type 2 diabetes mellitus (T2DM) with inadequate glucose control on metformin and dipeptidyl peptidase (DPP4) inhibitor therapy. MATERIALS AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryang, Soree, Kim, Sang Soo, Bae, Ji Cheol, Han, Ji Min, Kwon, Su Kyoung, Kim, Young Il, Nam‐Goong, Il Seong, Kim, Eun Sook, Kim, Mi‐kyung, Lee, Chang Won, Yoo, Soyeon, Koh, Gwanpyo, Kwon, Min Jeong, Park, Jeong Hyun, Kim, In Joo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541308/
https://www.ncbi.nlm.nih.gov/pubmed/35581902
http://dx.doi.org/10.1111/dom.14766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541308/
https://www.ncbi.nlm.nih.gov/pubmed/35581902
http://dx.doi.org/10.1111/dom.14766

Ejemplares similares